11/24/2025
On behalf of Genentech, you are invited to attend an expert-led educational presentation:
IMforte regimen: The first and only FDA-approved combination for maintenance treatment in 1L ES-SCLC
A review of the trial data for the IMforte regimen (TECENTRIQ + lurbinectedin)
⚫Target Audience: MDs, PAs, NPs, RNs, Residents, Fellows, and PharmDs
⚫Speaker: Mark Socinski, MD, Executive Medical Director, AdventHealth Cancer Institute
⚫Date & Time: Tuesday, December 2, 2025, 6:00 pm ET
Details and registration at https://loom.ly/b1Uhz4E